Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
Richard Benjamin, Chief Medical Officer at Cerus Corporation, shared on LinkedIn:
”The results of the ReCePI Phase III clinical study are now published.
A hearty congratulations to the many contributors and patients who have advanced the field of pathogen reduction for red blood cells (RBCs).
While transfusions are generally considered safe, they are always at risk for newly emerging infections (think historically of HIV, WNV, Zika, etc.) and for threats that are not covered by current testing (e.g., bacteria, malaria, etc.).
Technologies are FDA-approved to safeguard platelet and plasma transfusions, leaving an obvious gap with the most commonly transfused RBC components.
This work is bringing RBC pathogen reduction to reality and would not have been possible without generous funding from BARDA, a US agency with true foresight to protect patients against future and current threats to transfusion safety.”
Read the full article here.
Article: Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Authors: Michael E. Sekela, Edward L. Snyder, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Richard Benjamin, and the ReCePI Study Collaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis